Pasithea Therapeutics Corp.
KTTA
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$0.70
FAIR PRICE
$1.10
MARGIN
$0.40
P/E Ratio
N/A
Div. Yield
N/A
ROE
-97.9%
Average
Market Cap
$6M
Small-cap
COMING SOON
Get notified when KTTA's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Tiago Reis Marques
COUNTRY
US
HEADQUARTERS
Miami Beach
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate KTTA's fair price
Pasithea Therapeutics Corp.'s fair price of $1.10 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $0.70, KTTA trades 57.1% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting KTTA's risk profile.
RELATIVE · 30%
Comparing KTTA's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for KTTA, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate KTTA's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for KTTA.
Explore on BuliosFAQ
What is the fair price of KTTA?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Pasithea Therapeutics Corp. is $1.10. At the current market price of $0.70, KTTA trades 57.1% below its calculated fair value.
Is KTTA overvalued or undervalued?+
Pasithea Therapeutics Corp. is currently undervalued based on our valuation model. The stock trades at $0.70, which is 57.1% below the fair price of $1.10.
How often is KTTA's fair price updated?+
We update fair price calculations for KTTA daily after market close. The current fair price of $1.10 incorporates the latest market data and sector multiples.
What factors affect KTTA's fair price calculation?+
KTTA's fair price of $1.10 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -97.9%.
Is KTTA a good buy right now?+
At $0.70, KTTA trades 57.1% below our fair value estimate of $1.10. The stock is currently undervalued. ROE stands at -97.9% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does KTTA pay dividends?+
KTTA does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.